Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: A randomized double-blinded controlled trial

Wound Repair and Regeneration

Volumn 22, Issue 4, 2014, Pages 497-503

  Gomez Villa, Ramiro ^a   Aguilar Rebolledo, Francisco ^b   Lozano Platonoff, Adriana ^a   Teran Soto, Juan Miguel ^b   Fabian Victoriano, Maria Rosy ^a   Kresch Tronik, Nicole Stephanie ^a   Garrido Espíndola, Ximena ^a   Garcia Solis, Adriana ^a   Bondani Guasti, Augusto ^c   Bierzwinsky Sneider, Guillermo ^a   Contreras Ruiz, José ^a  

^a HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^b Center for Advanced Medicine (CIMA AC)   (Mexico)

^c Mexican Association of Pharmacology (AMEFAR)   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; GLUCOSE; HEMOGLOBIN A1C; PARACETAMOL; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR; ANGIOGENIC FACTOR; EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPLICATION SITE PAIN; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BURNING SENSATION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; DISTAL PARESTHESIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPITHELIZATION; FAINTNESS; FEMALE; GLUCOSE BLOOD LEVEL; GRANULATION TISSUE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREMOR; VOMITING; WOUND HEALING; AMPUTATION; CELL PROLIFERATION; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; EPIDEMIOLOGY; INTRALESIONAL DRUG ADMINISTRATION; MEXICO; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AMPUTATION; ANGIOGENESIS INDUCING AGENTS; CELL PROLIFERATION; DIABETIC FOOT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPIDERMAL GROWTH FACTOR; FEMALE; GRANULATION TISSUE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MEXICO; RECOMBINANT PROTEINS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84904618771     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12187     Document Type: Article

References (39)

1. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 (Suppl. 1): S11-66.
2. Steed DL, Attinger C, Colaizzi T, Crossland M, Franz M, Harkless L, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen 2006; 14: 680-692. (Pubitemid 44951308)
3. Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, del Rio A, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J 2006; 3: 232-239.
4. Fernandez-Montequin JI, Infante-Cristia E, Valenzuela-Silva C, Franco-Perez N, Savigne-Gutierrez W, Artaza-Sanz H, et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007; 4: 333-343. (Pubitemid 350264799)
5. Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A, Wasem J,. The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers. GMS Health Technol Assess 2010; 6: Doc12.
6. Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A, Wasem J,. The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): a health technology assessment (HTA). Exp Clin Endocrinol Diabetes 2011; 119: 472-479.
7. MacNeil S,. Progress and opportunities for tissue-engineered skin. Nature 2007; 445: 874-880.
8. Shah JM, Omar E, Pai DR, Sood S,. Cellular events and biomarkers of wound healing. Indian J Plast Surg 2012; 45: 220-228.
9. Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S,. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol 2000; 115: 245-253. (Pubitemid 30637194)
10. Cohen S,. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962; 237: 1555-1562.
11. Pastore S, Mascia F, Mariani V, Girolomoni G,. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008; 128: 1365-1374. (Pubitemid 351693180)
12. Gibbs S, Silva Pinto AN, Murli S, Huber M, Hohl D, Ponec M,. Epidermal growth factor and keratinocyte growth factor differentially regulate epidermal migration, growth, and differentiation. Wound Repair Regen 2000; 8: 192-203. (Pubitemid 30421522)
13. Krishnan ST, Quattrini C, Jeziorska M, Malik RA, Rayman G,. Neurovascular factors in wound healing in the foot skin of type 2 diabetic subjects. Diabetes Care 2007; 30: 3058-3062. (Pubitemid 350255246)
14. Acosta JB, del Barco DG, Vera DC, Savigne W, Lopez-Saura P, Guillen Nieto G, et al. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J 2008; 5: 530-539.
15. Berlanga-Acosta J,. Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J 2011; 8: 612-620.
16. Dinh T, Tecilazich F, Kafanas A, Doupis J, Gnardellis C, Leal E, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes 2012; 61: 2937-2947.
17. Brem H, Tomic-Canic M,. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007; 117: 1219-1222. (Pubitemid 46718408)
18. Dubuisson AS, Beuermann RW, Kline DG,. Sciatic nerve regeneration across gaps within collagen chambers: the influence of epidermal growth factor. J Reconstr Microsurg 1993; 9: 341-346, discussion 346.
19. Galkowska H, Wojewodzka U, Olszewski WL,. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 2006; 14: 558-565. (Pubitemid 44470072)
20. Toma JG, Pareek S, Barker P, Mathew TC, Murphy RA, Acheson A, et al. Spatiotemporal increases in epidermal growth factor receptors following peripheral nerve injury. J Neurosci 1992; 12: 2504-2515.
21. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P,. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18: 604-606.
22. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26: 1856-1861. (Pubitemid 36929133)
23. Lopez-Saura PA, Berlanga-Acosta J, Fernandez-Montequin J, Valenzuela-Silva C, Gonzalez-Diaz O, Savigne W, et al. Intralesional human recombinant epidermal growth factor for the treatment of advanced diabetic foot ulcer: from proof of concept to confirmation of efficacy and safety for the procedure. In:, Dinh T, editor. Global perspective on diabetic foot ulcerations. Rijeka, Croatia: InTech, 2011: 217-238.
24. Tiaka EK, Papanas N, Manolakis AC, Georgiadis GS,. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Perspect Vasc Surg Endovasc Ther 2012; 24: 37-44.
25. Armstrong DG,. The University of Texas Diabetic Foot Classification System. Ostomy Wound Manage 1996; 42: 60-61.
26. Fernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernandez F, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J 2009; 6: 432-443.
27. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54: e132-173.
28. Margolis DJ, Kantor J, Berlin JA,. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999; 22: 692-695. (Pubitemid 29220765)
29. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA,. Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care 2002; 25: 1835-1839. (Pubitemid 41071096)
30. Dougherty EJ,. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care 2008; 21: 568-575.
31. Langer A, Rogowski W,. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res 2009; 9: 115.
32. Fernandez-Montequin JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galan-Naranjo K, Ramirez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J 2009; 6: 67-72.
33. Yesil S, Akinci B, Yener S, Bayrakta F, Karabay O, Havitcioglu H, et al. Predictors of amputation in diabetics with foot ulcer: single center experience in a large Turkish cohort. Hormones (Athens) 2009; 8: 286-295.
34. Gershater MA, Londahl M, Nyberg P, Larsson J, Thorne J, Eneroth M, et al. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. Diabetologia 2009; 52: 398-407.
35. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, Harkless LB, et al. The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001; 18: 133-138. (Pubitemid 32238959)
36. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA,. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol 2000; 136: 1531-1535. (Pubitemid 32009274)
37. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36: 1033-1046.
38. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22: 382-387. (Pubitemid 29106890)
39. Weck M, Slesaczeck T, Paetzold H, Muench D, Nanning T, von Gagern G, et al. Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates. Cardiovasc Diabetol 2013; 12: 45.